Pemetrexed Market By Product Type (Injection, Oral Tablets), By Application (Lung Cancer, Mesothelioma), By End-User (Hospitals & Clinics, Oncology Centers), By Distribution Channel (Direct Sales, Distributors, Online Retailers), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Pemetrexed Market was valued at USD 2.5 billion in 2024-e and will surpass USD 4.1 billion by 2030; growing at a CAGR of 8.5% during 2025 - 2030.

The pemetrexed market has shown significant growth owing to its pivotal role in the treatment of various types of cancer, especially non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma. Pemetrexed, a chemotherapy drug, is used as a first-line treatment for these cancers and has demonstrated efficacy in both monotherapy and in combination with other drugs. As awareness of the drug's therapeutic benefits increases, demand for pemetrexed-based treatments is expected to rise, particularly in oncology settings.

Additionally, the growing prevalence of lung cancer, particularly in the aging population, coupled with advancements in cancer treatment protocols, is driving market growth. The drug's ability to target multiple pathways involved in cancer cell growth has positioned it as a key player in the oncology therapeutic landscape. As more healthcare providers embrace pemetrexed for its effectiveness, the market continues to expand, with emerging markets also contributing to its growth.

Injection Segment is Largest Owing to Efficacy in Cancer Treatment

The injection segment holds the largest share in the pemetrexed market due to its widespread use in treating lung cancer and mesothelioma. The intravenous form of pemetrexed is commonly preferred in clinical settings due to its higher bioavailability and faster onset of action compared to oral formulations. The injectable form is typically administered in hospitals and oncology centers under medical supervision, which ensures better management of any potential side effects and optimizes the therapeutic outcomes for cancer patients.

As the effectiveness of intravenous pemetrexed in reducing tumor size and improving patient survival rates continues to be supported by clinical research, this form remains the first choice for oncologists when treating patients with advanced lung cancer or mesothelioma. The demand for injectable pemetrexed is expected to remain robust, especially in regions with well-established healthcare systems and specialized oncology centers.

Lung Cancer Application is Largest Owing to High Prevalence

Lung cancer is the largest application segment for pemetrexed, driven by the high prevalence of the disease and its association with significant morbidity and mortality. Pemetrexed, when used as part of combination therapy or as a standalone treatment, has shown substantial efficacy in improving survival rates and quality of life for patients with non-small cell lung cancer. Lung cancer remains one of the most common types of cancer globally, particularly among older adults, making pemetrexed an essential part of modern oncological care.

Given the increasing incidence of lung cancer and advancements in diagnostic tools that enable earlier detection, the demand for effective treatments like pemetrexed is expected to rise. The drug's effectiveness in both advanced and metastatic stages of lung cancer has solidified its position as a cornerstone in the treatment regimen for this patient group, thereby ensuring continued growth in the lung cancer treatment segment.

Direct Sales Distribution Channel is Fastest Growing Owing to Direct Access to Healthcare Providers

The direct sales distribution channel is the fastest growing in the pemetrexed market, primarily driven by the direct access that manufacturers have to hospitals, oncology centers, and other medical institutions. By selling directly to healthcare providers, manufacturers can streamline the supply chain, reduce costs, and ensure that their products are available in the right hands at the right time. This model also allows manufacturers to provide tailored customer support, which is crucial for cancer treatments that require careful administration and monitoring.

The shift towards direct sales also enables greater product visibility and marketing opportunities for pharmaceutical companies, which can further drive adoption among healthcare professionals. As the healthcare industry continues to emphasize efficiency and cost-effectiveness, the direct sales channel is expected to gain further traction in the pemetrexed market.

North America is Largest Region Owing to Advanced Healthcare Infrastructure and Market Penetration

North America is the largest region in the pemetrexed market, owing to its advanced healthcare infrastructure, high levels of healthcare spending, and the established presence of oncology centers specializing in lung cancer and mesothelioma treatments. The United States, in particular, is the leading market for pemetrexed due to its high incidence of lung cancer, coupled with increasing awareness and adoption of effective cancer therapies.

In addition, the presence of well-established pharmaceutical companies and the availability of pemetrexed through multiple channels, including hospitals, oncology centers, and pharmacies, contribute to the region's dominance. The regulatory environment in North America also supports the rapid approval and distribution of innovative cancer treatments, ensuring that pemetrexed remains an integral part of oncology regimens. With ongoing advancements in cancer treatment protocols and increasing support for cancer research, North America is expected to continue its leadership position in the pemetrexed market.

Competitive Landscape

The pemetrexed market is competitive, with several key pharmaceutical companies offering the drug in various formulations. Leading players include Eli Lilly and Co., which developed the branded version of pemetrexed, Alimta. Other pharmaceutical companies are entering the market with generic versions of pemetrexed, making the drug more accessible to a wider range of patients.

As competition intensifies, companies are focusing on expanding their product offerings, improving drug formulations, and enhancing patient support services. Additionally, ongoing research into combining pemetrexed with other novel cancer therapies is likely to drive further market growth. Competitive dynamics will also be influenced by pricing strategies, particularly in regions where access to cancer drugs is a concern. Companies that can navigate the complex regulatory landscape and ensure effective distribution networks will be well-positioned to capture a larger market share in the coming years.

List of Leading Companies:

• Eli Lilly and Company
• Teva Pharmaceutical Industries
• Mylan N.V. (Viatris)
• Fresenius Kabi
• Sandoz (Novartis)
• Pfizer
• Amgen Inc.
• Boehringer Ingelheim
• Dr. Reddy's Laboratories
• Cipla
• Sun Pharmaceutical Industries
• Bristol Myers Squibb
• Zydus Cadila
• Hikma Pharmaceuticals
• Apotex

Recent Developments:

• In December 2024, Eli Lilly and Company announced the launch of a new formulation of pemetrexed for advanced lung cancer treatment.
• In November 2024, Teva Pharmaceutical Industries introduced a new generic version of pemetrexed in key markets.
• In October 2024, Mylan N.V. (Viatris) received FDA approval for its new pemetrexed injection for mesothelioma patients.
• In September 2024, Sandoz (Novartis) expanded its pemetrexed portfolio with a new patient-friendly oral formulation.
• In August 2024, Pfizer entered into a partnership with oncology centers to improve access to pemetrexed for lung cancer patients.

Report Scope: